NKTR-102 + Eribulin + Ixabepilone + Vinorelbine + Gemcitabine + Paclitaxel + Docetaxel + Nab-paclitaxel

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Metastasis

Conditions

Metastasis, Breast Cancer

Trial Timeline

Nov 1, 2016 → Jul 1, 2020

NCT ID

NCT02915744

About NKTR-102 + Eribulin + Ixabepilone + Vinorelbine + Gemcitabine + Paclitaxel + Docetaxel + Nab-paclitaxel

NKTR-102 + Eribulin + Ixabepilone + Vinorelbine + Gemcitabine + Paclitaxel + Docetaxel + Nab-paclitaxel is a phase 3 stage product being developed by Nektar Therapeutics for Metastasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02915744. Target conditions include Metastasis, Breast Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02915744	Phase 3	Completed	Nov 1, 2016	Jul 1, 2020	Metastasis

Competing Products

20 competing products in Metastasis

See all competitors

Product	Company	Stage	Hype Score
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + Leucovorin	Eli Lilly	Phase 1	33
DS-8201a + Ritonavir + Itraconazole	Daiichi Sankyo	Phase 1	33
LY2940680	Eli Lilly	Phase 1	33
LY2835219	Eli Lilly	Phase 1	33
Drug Cocktail + Abemaciclib	Eli Lilly	Phase 1	33
Olaratumab + Doxorubicin + Vincristine + Irinotecan + Ifosfamide	Eli Lilly	Phase 1	33
Tanezumab	Eli Lilly	Phase 3	77
AZD2281	AstraZeneca	Phase 1	33
AZD2281 + Bevacizumab	AstraZeneca	Phase 1	33
Cetuximab + Oxaliplatin	Merck	Phase 2	52
MK-6837 + Pembrolizumab + Rescue Medications	Merck	Phase 1	33
5-FU + folinic acid + irinotecan + cetuximab + bevacizumab	Merck	Phase 3	77
Pembrolizumab + Favezelimab + Favezelimab/Pembrolizumab + Vibostolimab + Pembrolizumab/Vibostolimab	Merck	Phase 1/2	41
200 mg of pembrolizumab + V938	Merck	Phase 1	33
Gebasaxturev + Pembrolizumab	Merck	Phase 1/2	41
Pimasertib + Dacarbazine	Merck	Phase 2	52
Paclitaxel plus PTK787	Novartis	Phase 1	33
Zoledronic acid	Novartis	Phase 3	77
Zoledronic acid	Novartis	Phase 3	77
zoledronic acid	Novartis	Approved	85

Other Products from Nektar Therapeutics

NKTR-181 BID tablets + Placebo to match NKTR-181 BID tabletsPhase 3

NKTR-102 + Treatment of Physician's Choice (TPC)Phase 3

NKTR-181 BID tabletsPhase 3

NKTR-255 at 1.5 µg/kg + NKTR-255 at 3.0 μg/kg + NKTR-255 at 3.0/6.0 μg/kgPhase 2/3

aerosolized vancomycin or gentamicinPhase 2